NCT00016627

Brief Summary

To map the gene (or genes) for familial pulmonary fibrosis.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Aug 2000

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2000

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

May 19, 2001

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 21, 2001

Completed
4.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2005

Completed
Last Updated

February 18, 2016

Status Verified

November 1, 2005

First QC Date

May 19, 2001

Last Update Submit

February 17, 2016

Conditions

Pulmonary FibrosisLung DiseasesLung Diseases, Interstitial

Eligibility Criteria

Age20 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
No eligibility criteria

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Related Publications (5)

  • Wahidi MM, Speer MC, Steele MP, Brown KK, Schwarz MI, Schwartz DA. Familial pulmonary fibrosis in the United States. Chest. 2002 Mar;121(3 Suppl):30S. doi: 10.1378/chest.121.3_suppl.30s. No abstract available.

    PMID: 11893669BACKGROUND

  • Savov JD, Brass DM, Berman KG, McElvania E, Schwartz DA. Fibrinolysis in LPS-induced chronic airway disease. Am J Physiol Lung Cell Mol Physiol. 2003 Oct;285(4):L940-8. doi: 10.1152/ajplung.00102.2003. Epub 2003 Jun 20.

    PMID: 12818888BACKGROUND

  • Garantziotis S, Steele MP, Schwartz DA. Pulmonary fibrosis: thinking outside of the lung. J Clin Invest. 2004 Aug;114(3):319-21. doi: 10.1172/JCI22497.

    PMID: 15286797BACKGROUND

  • Steele MP, Speer MC, Loyd JE, Brown KK, Herron A, Slifer SH, Burch LH, Wahidi MM, Phillips JA 3rd, Sporn TA, McAdams HP, Schwarz MI, Schwartz DA. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med. 2005 Nov 1;172(9):1146-52. doi: 10.1164/rccm.200408-1104OC. Epub 2005 Aug 18.

    PMID: 16109978BACKGROUND

  • Garantziotis S, Zudaire E, Trempus CS, Hollingsworth JW, Jiang D, Lancaster LH, Richardson E, Zhuo L, Cuttitta F, Brown KK, Noble PW, Kimata K, Schwartz DA. Serum inter-alpha-trypsin inhibitor and matrix hyaluronan promote angiogenesis in fibrotic lung injury. Am J Respir Crit Care Med. 2008 Nov 1;178(9):939-47. doi: 10.1164/rccm.200803-386OC. Epub 2008 Aug 14.

    PMID: 18703791DERIVED

MeSH Terms

Conditions

Pulmonary FibrosisLung DiseasesLung Diseases, Interstitial

Condition Hierarchy (Ancestors)

Respiratory Tract DiseasesFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Mark Steele

    Duke University

Study Design

Study Type
observational
Sponsor Type
NIH

Study Record Dates

First Submitted

May 19, 2001

First Posted

May 21, 2001

Study Start

August 1, 2000

Study Completion

July 1, 2005

Last Updated

February 18, 2016

Record last verified: 2005-11